EyeintheskyMarch 17, 2022
Many people around the world may have wondered how it is possible that billions of „vaccine doses“ can be made available at the push of a button, and all governments worldwide have agreed to torture their populations until everyone is dosed with a vaccine at least three times or even more – from babies to hospice residents.
To understand the organisations and structures behind mRNA-technology that has been built over the past two decades, one must look at the history of mRNA technology:
Beginning in 1985, researcher Katalin Karikó and later her colleague Drew Weissmann were working on mRNA-technology in Pennsylvania. The idea was to use modified mRNAs to manipulate cellular mechanisms for making proteins so that they could be used for a variety of clinical purposes. A major difficulty was that the introduced mRNA was so unstable that it was immediately attacked and degraded by the body’s immune system – and, it caused a lot of unwanted heavy side effects. After two decades of experimentation and research, they found that – when they modified selected nucleosides – the body’s own recognition of artificial RNA strands was suppressed, thereby avoiding a dangerous immune cascade. It was understood how to „trick“ the body’s immune system, which normally has a healthy response. (1) For this findings, published in 2005, Karikó and Weissman received grants from the from the National Institute of Allergy and Infectious Diseases (NIAID) totaling $2.3 million for six projects. (2)
Karikó and Weissman’s findings attracted the attention of Derrick Rossi, a stem cell biologist who initially thought it might be the key to growing stem cells. He and his colleagues at Harvard and MIT continued to do research, founding the biotech startup Moderna („mode-RNA“) in 2010. Meanwhile, a Turkish-German physician couple, Ugur Sahin and Özlem Türeci, founded BioNTech in Germany in 2008. Sahin, an oncologist and inventor, co-founded Ganymed Pharmaceuticals with Özlem Türeci, a physician and immunologist, to develop individualized cancer immunotherapies based on genetic engineering. (3)
While NIAID was funding basic science innovation, the U.S. Department of Defense was making high-risk investments in RNA vaccine technology through its Defense Advanced Research Projects Agency (DARPA), the research arm of the Pentagon („Department of Defense“ = DOD). In 2011, CureVac (a Sanofi-affiliated company) and In-Cell-Art received $33.1 million from DARPA to further develop their „vaccine platforms“ based on RNA technologies and to test product candidates.
In October 2013, DARPA awarded Moderna nearly $25 million to research and develop potential mRNA compounds under DARPA’s Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program: Developing technologies to rapidly detect and respond to threats from natural and man-made diseases and toxins. Back in March 2013, Moderna received funding from DARPA – and the second round of funds was to be used – according to the release – primarily to support vaccine and antibody development to protect against chikungunya infections. (4) Moderna has received $955 million from BARDA – Biomedical Advanced Research and Development Authority – in recent years to develop a Covid-19 vaccine based on mRNA technology in collaboration with the NIH (National Institutes of Health). However, in all their 127 patents and 154 patent applications, nowhere did they state having received grant money from the government as they should have. (5)
Who really believes in „coincidence“ that this – truely important – fact is kept secret? After all, there is a duty of disclosure torwards the public – why are Moderna’s and DARPA’s collaboration concealed – with the knowledge of the institutions?
Pfizer also received over $7.6 million from DARPA in Q4 2013: „Pfizer will conduct a research and development program aimed at developing a technology platform to identify and then induce the production of protective antibodies against an emerging pathogen directly in an infected or exposed individual“ .(6) DOD wrote in its summary of recent contracts. „Identifying the antigen and inducing antibody production in vivo would eliminate some of the time-consuming steps currently required to develop, manufacture and administer a vaccine. Although the project is clearly at a very early stage – and the budget is small by biopharma standards – the potential impact of the work is large and far-reaching. Success would overturn traditional vaccine practices.“ (7)
mRNA technology – a „design platform“.
It is important to understand that the mRNA technology is a technology platform that can be used for many different purposes. The preassumption is that special cell strands can be integrated into the body to produce certain proteins – „designer proteins“ for various purposes – by means of mRNA sequences that were predefined and manufactured in a lab, thus genetically manipulating the body at the cellular level. This is a concept, a basic principle they intend to apply to a wide variety of medical problems. This kind of simple logic, however, follows a rather primitive approach of understanding complex organisms, which carries a lot of dangers. It does not consider multiple cascade effects in the whole body when changing single proteins – which are the basic building blocks of life! If you change even one cogwheel in a Swiss precision clock, it can cause the whole gear to stop. The body is such a precision clock, where all processes are intertwined. The artificial generation of foreign – pathogenic – proteins („spike proteins“) by introducing modified RNA sequences wrapped in artificial „envelopes“ (lipid nanoparticles) can trigger cascades of subsequent reactions. You don’t have to be a highly endowed scientist to draw this conclusion.
Calling the mRNA injection of genetically manipulating mRNA substances a „vaccine“ is part of a global disinformation campaign. Officials have changed the definition of „vaccine“ several times in the meantime so that experimental mRNA substances can be labeled as such.
In 2013 – the same year that DARPA began funding mRNA research from Pfizer, BioNTech hired Katalin Karikó as Senior Vice President to oversee the development of their mRNA technology aimed at pandemic preparedness. And – BioNTech sold its former company Ganymede in 2016 for $1.6 billion.
In 2018, Biontech and Pfizer announced their collaboration regarding the development of flu vaccines based on mRNA technology. Neither corresponding Pfizer patents nor Biontech patents indicate that they received DARPA funds.
Start button „pandemic“ in December 2019
It was like pushing a start button: A whole machinery was set into motion from the alleged outbreak in Wuhan in December 2019: Virus isolation, PCR tests, „vaccine development“, proclamation of a pandemic, lockdowns, start of clinical trials in March 2020 by Moderna, followed by Biontech/Pfizers trials starting in April 2020, DOD contracts for the production of billions of „vaccine doses“, worldwide changing of laws regarding public behaviour, forcing mask wearing and social distancing, rules for daily testing and torturing children in schools, the fear mongering media were repeating the same script worldwide while independent outlets fell under censorship to silence alternative voices.
From January 21-24, 2020, the World Economic Forum met in Davos under the auspices of CEPI – „Coalition for Epidemic Preparedness Innovations“: CEPI is a WEF-Gates partnership – and contracts Seattle-based Moderna to produce an mRNA vaccine against 2019-nCoV: „The Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has collaborated with Moderna to develop the vaccine.“ (9)
So the „Mode-RNA vaccine“ was already available before the socalled „outbreak of a global pandemic.“
DARPA entered into contracts to produce and deliver a total of 1.7 billion doses of vaccine to U.S. – initially – with Pfizer and Moderna in the summer of 2020, as well as six other manufacturers:
Pfizer’s July 21, 2020 contract with the Department of Defense for the production and delivery of „vaccines“ states that they have contracted for $10 BILLION for 600 million doses of vaccine. Of particular note is the fact that this contract was first sent out on November 14, 2019, and the first revision was made on January 30, 2020 – before „the pandemic broke out“ (see p. 56 – link under References). The agreement indicates that 16 different lots of mRNA and 16 lipid compositions will be shipped without disclosing anything about the content. (10) The company McKesson is in charge of mixing the components to deliver in the vials to the institutions and practioners. At minimum 16×16 mixtures are possible, and, if they also experiment with the doses, the amount of possibles charges is innumerable.
In the contract with Moderna dated August 09, 2020, the contract value is stated with US$ 1,525,000,000.00 over 500 million doses of vaccine (100µg dose), and 33 different lots are listed, not disclosing anything about the content. (11)
Die Corona-Pandemie: Rückschau und Dokumentation 